Offit says the CDC data were not limited to babies who received antibodies through the maternal vaccine or monoclonal antibody injections but rather included all RSV-related infant hospitalizations. The other option is for the infant to receive a monoclonal antibody directly via injection. There are now two monoclonal antibody options: Sanofi and AstraZeneca’s nirsevimab, which was approved in 2023 and is the subject of the recent efficacy studies. “I tried my best at home for her and eventually decided that she was too dehydrated and needed to go to the hospital,” Carroll says. “She was admitted for about three and a half days, and she needed a lot of hydration and then antibiotics for the secondary bacterial pneumonia, which is one of the concerns with RSV,” Carroll says.